Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial

In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatment-related outcomes of the AF patients with heart failu...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2021-04, Vol.143 (14), p.1377-1390
Main Authors: Packer, Douglas L, Piccini, Jonathan P, Monahan, Kristi H, Al-Khalidi, Hussein R, Silverstein, Adam P, Noseworthy, Peter A, Poole, Jeanne E, Bahnson, Tristram D, Lee, Kerry L, Mark, Daniel B
Format: Article
Language:English
Subjects:
Ablation Techniques - methods
Aged
Atrial Fibrillation - drug therapy
Clinical Trials as Topic
Female
Heart Failure - complications
Humans
Male
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatment-related outcomes of the AF patients with heart failure enrolled in the CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation). The CABANA trial randomized 2204 patients with AF who were ≥65 years old or II at baseline and form the subject of this article. The CABANA trial's primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Of the 778 patients with heart failure enrolled in CABANA, 378 were assigned to ablation and 400 to drug therapy. Ejection fraction at baseline was available for 571 patients (73.0%), and 9.3% of these had an ejection fraction
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.120.050991